Symbols / IVVD $1.62 -3.29%
IVVD Chart
About
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 456.39M |
| Enterprise Value | 247.74M | Income | -52.49M | Sales | 53.43M |
| Book/sh | 0.86 | Cash/sh | 0.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 122 | IPO | — |
| P/E | — | Forward P/E | -40.38 | PEG | — |
| P/S | 8.54 | P/B | 1.88 | P/C | — |
| EV/EBITDA | -4.52 | EV/Sales | 4.64 | Quick Ratio | 7.06 |
| Current Ratio | 7.24 | Debt/Eq | 1.03 | LT Debt/Eq | — |
| EPS (ttm) | -0.30 | EPS next Y | -0.04 | EPS Growth | — |
| Revenue Growth | 24.50% | Earnings | 2026-05-07 | ROA | -17.09% |
| ROE | -33.97% | ROIC | — | Gross Margin | 92.99% |
| Oper. Margin | -72.96% | Profit Margin | -98.25% | Shs Outstand | 282.59M |
| Shs Float | 167.59M | Short Float | 9.73% | Short Ratio | 9.14 |
| Short Interest | — | 52W High | 3.07 | 52W Low | 0.46 |
| Beta | 0.61 | Avg Volume | 3.29M | Volume | 2.17M |
| Target Price | $10.00 | Recom | Strong_buy | Prev Close | $1.67 |
| Price | $1.61 | Change | -3.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$10.00
Mean price target
2. Current target
$1.59
Latest analyst target
3. DCF / Fair value
$-2.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.59
Low
$10.00
High
$10.00
Mean
$10.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-26 | reit | BTIG | Buy → Buy | $10 |
| 2025-12-23 | reit | BTIG | Buy → Buy | $10 |
| 2025-12-22 | init | BTIG | — → Buy | $10 |
| 2025-11-25 | down | D. Boral Capital | Buy → Hold | — |
| 2025-11-03 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-10-31 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-10-06 | main | D. Boral Capital | Buy → Buy | $2 |
| 2025-10-06 | init | Cantor Fitzgerald | — → Overweight | $10 |
| 2025-08-27 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-08-25 | main | D. Boral Capital | Buy → Buy | $1 |
| 2025-08-19 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-06-26 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-06-26 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-05-28 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-05-16 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-26 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-20 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-03-05 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-02-24 | reit | HC Wainwright & Co. | Buy → Buy | $10 |
- Invivyd (NASDAQ:IVVD) Stock Price Up 6.3% - Still a Buy? - MarketBeat Wed, 11 Mar 2026 18
- New Invivyd staff get options on 192,000 shares at $1.69 each - Stock Titan Mon, 02 Mar 2026 21
- Insider Sale: Chief Scientific Officer of $IVVD Sells 18,189 Shares - Quiver Quantitative hu, 19 Feb 2026 08
- Why Analysts See Invivyd (IVVD) Story Shifting After REVOLUTION Program And US$10 Target - Yahoo Finance Fri, 09 Jan 2026 08
- Will Invivyd's DECLARATION Trial Send IVVD Stock Higher In 2026? - RTTNews Fri, 09 Jan 2026 08
- Invivyd, Inc.'s (NASDAQ:IVVD) 26% Share Price Plunge Could Signal Some Risk - simplywall.st hu, 29 Jan 2026 08
- $IVVD stock is up 25% today. Here's what we see in our data. - Quiver Quantitative Mon, 22 Dec 2025 08
- How Recent Price Target Resets Are Rewriting The Story For Invivyd (IVVD) - Yahoo Finance Sat, 24 Jan 2026 08
- New study maps COVID protection to antibody levels, not variants - Stock Titan ue, 24 Feb 2026 08
- Institutional investors in Invivyd, Inc. (NASDAQ:IVVD) see US$113m decrease in market cap last week, although long-term gains have benefitted them. - simplywall.st ue, 27 Jan 2026 08
- Invivyd, Inc. Stock (IVVD) Opinions on Q3 2025 Financial Results and FDA Clearance | IVVD Stock News - Quiver Quantitative Fri, 14 Nov 2025 08
- Does Invivyd’s (IVVD) Index Debut Reveal a Turning Point in Its Biotech Credibility? - Yahoo Finance hu, 25 Dec 2025 08
- New antibody shot aims to offer vaccine-alternative protection from COVID - Stock Titan ue, 23 Dec 2025 08
- $IVVD stock is up 43% today. Here's what we see in our data. - Quiver Quantitative Fri, 14 Nov 2025 08
- Invivyd, Inc. (IVVD) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance hu, 06 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 40627 | 63350.0 | — | Sale at price 1.54 - 1.58 per share. | DUKE WILLIAM E. JR. | Chief Financial Officer | — | 2026-02-18 00:00:00 | D |
| 1 | 67710 | 105581.0 | — | Sale at price 1.54 - 1.58 per share. | ANDERSEN JILL | Officer | — | 2026-02-18 00:00:00 | D |
| 2 | 37581 | 58600.0 | — | Sale at price 1.54 - 1.58 per share. | ALLEN ROBERT D III | Officer | — | 2026-02-18 00:00:00 | D |
| 3 | 40627 | 63350.0 | — | Sale at price 1.54 - 1.58 per share. | GREEN JULIE | Officer | — | 2026-02-18 00:00:00 | D |
| 4 | 40627 | 63350.0 | — | Sale at price 1.54 - 1.58 per share. | LEE EDWARD TIMOTHY | Officer | — | 2026-02-18 00:00:00 | D |
| 5 | 99000 | nan | — | — | DUKE WILLIAM E. JR. | Chief Financial Officer | — | 2026-02-13 00:00:00 | D |
| 6 | 165000 | nan | — | — | ANDERSEN JILL | Officer | — | 2026-02-13 00:00:00 | D |
| 7 | 99000 | nan | — | — | ALLEN ROBERT D III | Officer | — | 2026-02-13 00:00:00 | D |
| 8 | 99000 | nan | — | — | GREEN JULIE | Officer | — | 2026-02-13 00:00:00 | D |
| 9 | 99000 | nan | — | — | LEE EDWARD TIMOTHY | Officer | — | 2026-02-13 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -53.45M | -173.76M | -200.78M | -204.02M |
| TotalUnusualItems | 0.00 | -4.97M | -21.77M | -7.50M |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -4.97M | -21.77M | -7.50M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -52.49M | -169.93M | -198.64M | -241.32M |
| ReconciledDepreciation | 2.11M | 3.11M | 2.03M | 462.00K |
| ReconciledCostOfRevenue | 3.75M | 1.62M | 0.00 | |
| EBITDA | -53.45M | -173.76M | -205.75M | -225.80M |
| EBIT | -55.56M | -176.88M | -207.78M | -226.26M |
| NormalizedIncome | -52.49M | -169.93M | -193.67M | -219.54M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -52.49M | -169.93M | -198.64M | -241.32M |
| TotalExpenses | 108.99M | 202.26M | 207.78M | 226.26M |
| TotalOperatingIncomeAsReported | -55.56M | -176.88M | -212.76M | -248.03M |
| DilutedAverageShares | 118.56M | 109.53M | 108.27M | 42.62M |
| BasicAverageShares | 118.56M | 109.53M | 108.27M | 42.62M |
| DilutedEPS | -1.43 | -1.81 | -2.23 | -5.32 |
| BasicEPS | -1.43 | -1.81 | -2.23 | -5.32 |
| DilutedNIAvailtoComStockholders | -52.49M | -169.93M | -198.64M | -241.32M |
| NetIncomeCommonStockholders | -52.49M | -169.93M | -198.64M | -241.32M |
| NetIncome | -52.49M | -169.93M | -198.64M | -241.32M |
| NetIncomeIncludingNoncontrollingInterests | -52.49M | -169.93M | -198.64M | -241.32M |
| NetIncomeContinuousOperations | -52.49M | -169.93M | -198.64M | -241.32M |
| PretaxIncome | -52.49M | -169.93M | -198.64M | -241.32M |
| OtherIncomeExpense | 3.07M | 6.95M | 9.14M | -15.06M |
| OtherNonOperatingIncomeExpenses | 3.07M | 6.95M | 14.12M | 6.71M |
| SpecialIncomeCharges | 0.00 | -4.97M | -4.40M | -7.50M |
| OtherSpecialCharges | 4.97M | 4.40M | 7.50M | |
| GainOnSaleOfSecurity | -17.37M | |||
| OperatingIncome | -55.56M | -176.88M | -207.78M | -226.26M |
| OperatingExpense | 105.24M | 200.64M | 207.78M | 226.26M |
| ResearchAndDevelopment | 38.31M | 137.25M | 158.66M | 179.21M |
| SellingGeneralAndAdministration | 66.93M | 63.39M | 49.12M | 47.04M |
| GeneralAndAdministrativeExpense | 66.93M | 63.39M | 49.12M | 47.04M |
| OtherGandA | 35.67M | 33.48M | 21.80M | 25.89M |
| SalariesAndWages | 31.26M | 29.91M | 27.32M | 21.15M |
| GrossProfit | 49.68M | 23.77M | 0.00 | |
| CostOfRevenue | 3.75M | 1.62M | 0.00 | |
| TotalRevenue | 53.43M | 25.38M | 0.00 | 0.00 |
| OperatingRevenue | 53.43M | 25.38M | 0.00 | 0.00 |
| Line Item | 2022-12-31 | 2021-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 468.75K | ||
| OrdinarySharesNumber | 281.99M | 119.84M | 110.16M | 109.04M |
| ShareIssued | 281.99M | 119.84M | 110.16M | 109.04M |
| TotalDebt | 2.49M | 1.30M | 2.17M | 3.72M |
| TangibleBookValue | 241.54M | 67.54M | 177.47M | 355.97M |
| InvestedCapital | 241.54M | 67.54M | 177.47M | 355.97M |
| WorkingCapital | 213.30M | 38.70M | 174.59M | 351.89M |
| NetTangibleAssets | 241.54M | 67.54M | 177.47M | 355.97M |
| CapitalLeaseObligations | 2.49M | 1.30M | 2.17M | 3.72M |
| CommonStockEquity | 241.54M | 67.54M | 177.47M | 355.97M |
| TotalCapitalization | 241.54M | 67.54M | 177.47M | 355.97M |
| TotalEquityGrossMinorityInterest | 241.54M | 67.54M | 177.47M | 355.97M |
| StockholdersEquity | 241.54M | 67.54M | 177.47M | 355.97M |
| GainsLossesNotAffectingRetainedEarnings | -41.00K | -5.00K | -13.00K | -272.00K |
| OtherEquityAdjustments | -41.00K | -5.00K | -13.00K | -272.00K |
| TreasuryStock | 0.00 | 0.00 | 0.00 | 0.00 |
| RetainedEarnings | -954.48M | -901.99M | -732.07M | -533.43M |
| AdditionalPaidInCapital | 1.20B | 969.53M | 909.54M | 889.66M |
| CapitalStock | 28.00K | 12.00K | 11.00K | 11.00K |
| CommonStock | 28.00K | 12.00K | 11.00K | 11.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 35.34M | 61.98M | 51.71M | 27.20M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.18M | 0.00 | 1.42M | 2.17M |
| OtherNonCurrentLiabilities | 700.00K | 1.00K | 12.00K | |
| PreferredSecuritiesOutsideStockEquity | 0.00 | |||
| DuetoRelatedPartiesNonCurrent | 0.00 | 700.00K | ||
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 1.18M | 0.00 | 722.00K | 2.17M |
| LongTermCapitalLeaseObligation | 1.18M | 0.00 | 722.00K | 2.17M |
| CurrentLiabilities | 34.16M | 61.98M | 50.29M | 25.03M |
| OtherCurrentLiabilities | 52.00K | 27.00K | 35.00K | 44.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.31M | 1.30M | 1.44M | 1.56M |
| CurrentCapitalLeaseObligation | 1.31M | 1.30M | 1.44M | 1.56M |
| PensionandOtherPostRetirementBenefitPlansCurrent | 5.75M | 3.92M | 10.75M | 5.99M |
| PayablesAndAccruedExpenses | 27.05M | 56.73M | 38.06M | 17.44M |
| CurrentAccruedExpenses | 13.30M | 46.28M | 30.11M | 15.93M |
| Payables | 13.74M | 10.45M | 7.95M | 1.52M |
| AccountsPayable | 13.74M | 10.45M | 7.95M | 1.52M |
| TotalAssets | 276.88M | 129.51M | 229.18M | 383.17M |
| TotalNonCurrentAssets | 29.42M | 28.83M | 4.30M | 6.25M |
| OtherNonCurrentAssets | 25.61M | 25.94M | 175.00K | 191.00K |
| NetPPE | 3.81M | 2.89M | 4.12M | 6.06M |
| GrossPPE | 3.81M | 2.89M | 4.12M | 6.06M |
| OtherProperties | 3.81M | 2.89M | 4.12M | 6.06M |
| CurrentAssets | 247.47M | 100.68M | 224.88M | 376.92M |
| OtherCurrentAssets | 1.45M | 3.73M | ||
| PrepaidAssets | 4.47M | 16.44M | 23.31M | 4.55M |
| Inventory | 263.00K | 0.00 | ||
| FinishedGoods | 263.00K | 0.00 | ||
| Receivables | 14.60M | 11.17M | 933.00K | 377.00K |
| AccruedInterestReceivable | 676.00K | 263.00K | 933.00K | 377.00K |
| AccountsReceivable | 13.92M | 10.91M | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 226.69M | 69.35M | 200.64M | 371.99M |
| OtherShortTermInvestments | 0.00 | 279.92M | 49.19M | |
| CashAndCashEquivalents | 226.69M | 69.35M | 200.64M | 92.08M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -58.29M | -170.63M | -173.78M | -221.69M |
| RepurchaseOfCapitalStock | -633.00K | 0.00 | -1.00K | -4.00K |
| IssuanceOfCapitalStock | 215.93M | 39.28M | 0.00 | 0.00 |
| CapitalExpenditure | -155.00K | -140.00K | -615.00K | -1.71M |
| EndCashPosition | 226.69M | 69.35M | 200.64M | 92.08M |
| BeginningCashPosition | 69.35M | 200.64M | 92.08M | 542.22M |
| EffectOfExchangeRateChanges | 0.00 | 8.00K | 0.00 | |
| ChangesInCash | 157.34M | -131.30M | 108.56M | -450.15M |
| FinancingCashFlow | 215.63M | 39.33M | 1.04M | 506.00K |
| CashFlowFromContinuingFinancingActivities | 215.63M | 39.33M | 1.04M | 506.00K |
| NetOtherFinancingCharges | -336.00K | -597.00K | -149.00K | -3.38M |
| ProceedsFromStockOptionExercised | 665.00K | 643.00K | 1.20M | 510.00K |
| NetPreferredStockIssuance | 0.00 | 335.16M | ||
| PreferredStockIssuance | 0.00 | 335.16M | ||
| NetCommonStockIssuance | 215.30M | 39.28M | -1.00K | -4.00K |
| CommonStockPayments | -633.00K | 0.00 | -1.00K | -4.00K |
| CommonStockIssuance | 215.93M | 39.28M | 0.00 | 0.00 |
| InvestingCashFlow | -155.00K | -140.00K | 280.68M | -230.67M |
| CashFlowFromContinuingInvestingActivities | -155.00K | -140.00K | 280.68M | -230.67M |
| NetInvestmentPurchaseAndSale | 0.00 | 281.30M | -228.96M | -50.63M |
| SaleOfInvestment | 0.00 | 372.50M | 69.00M | 138.00M |
| PurchaseOfInvestment | 0.00 | -91.20M | -297.96M | -188.63M |
| NetPPEPurchaseAndSale | -155.00K | -140.00K | -615.00K | -1.71M |
| PurchaseOfPPE | -155.00K | -140.00K | -615.00K | -1.71M |
| OperatingCashFlow | -58.13M | -170.49M | -173.16M | -219.99M |
| CashFlowFromContinuingOperatingActivities | -58.13M | -170.49M | -173.16M | -219.99M |
| ChangeInWorkingCapital | -19.69M | -23.47M | 5.89M | -16.13M |
| ChangeInOtherCurrentLiabilities | -1.20M | -2.37M | -869.00K | -436.00K |
| ChangeInOtherCurrentAssets | -77.00K | 141.00K | 16.00K | 3.11M |
| ChangeInPayablesAndAccruedExpense | -27.64M | 11.37M | 25.63M | -39.17M |
| ChangeInAccruedExpense | -30.85M | 8.95M | 19.16M | -34.87M |
| ChangeInPayable | 3.21M | 2.42M | 6.47M | -4.30M |
| ChangeInAccountPayable | 3.21M | 2.42M | 6.47M | -4.30M |
| ChangeInPrepaidAssets | 12.92M | 3.19M | -18.89M | 20.37M |
| ChangeInInventory | -373.00K | -24.89M | 0.00 | |
| ChangeInReceivables | -3.34M | -10.91M | 0.00 | |
| ChangesInAccountReceivables | -3.34M | -10.91M | 0.00 | |
| OtherNonCashItems | 298.00K | 66.00K | ||
| StockBasedCompensation | 11.64M | 19.79M | 18.68M | 21.65M |
| AmortizationOfSecurities | 0.00 | -1.12M | -2.02M | 1.43M |
| DepreciationAmortizationDepletion | 2.11M | 3.11M | 2.03M | 462.00K |
| DepreciationAndAmortization | 2.11M | 3.11M | 2.03M | 462.00K |
| Depreciation | 2.11M | 3.11M | 2.03M | 462.00K |
| OperatingGainsLosses | 17.37M | |||
| GainLossOnInvestmentSecurities | 17.37M | |||
| NetIncomeFromContinuingOperations | -52.49M | -169.93M | -198.64M | -241.32M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for IVVD
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|